Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-863233 in advanced solid tumors
NCT00886782Phase 2Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- May 2009
- Primary completion
- Aug 2010
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of BMS-863233 in solid tumor (advanced stage) and metastatic solid tumors, sponsored by Bristol Myers Squibb. Primary endpoints: Number of Participants With Dose Limiting Toxicities at 28 days, Number of Participants With Adverse Events up to 14 months and 2 more. Started May 2009; status: terminated.
02
Drugs
BMS-863233
03
Conditions
solid tumor (advanced stage)metastatic solid tumors
Beyond the preview
Go deeper on NCT00886782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00886782.